Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible Hepatocellular Carcinoma
PaperCitations, authors & open-access status
mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible Hepatocellular Carcinoma is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 1 citations, 2024 year and closed oa status.
1
Citations
2024
Year
closed
OA Status